Health Care · Surgical & Medical Instruments & Apparatus

PDEX PRO DEX INC SEC Filings & Insider Trading Activity 2026

company
CIK 788920106 filings
Russell 2000

PDEX at a glance

PRO DEX INC (PDEX, SEC CIK 788920) filed its latest 10-K annual report on September 3, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as September 14, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended June 30, 2026 (FY2026), PRO DEX INC (PDEX) reported revenue of $77.5 million (up 16.5% from FY2025) and net income of $13.7 million. Diluted EPS was $4.12.
  • As of September 30, 2026, 17 institutional investment managers tracked by SignalX reported holding PRO DEX INC (PDEX) shares worth $34.7 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Van Kirk Richard Lee Jr on September 11, 2026 of 290 shares at $58.94 per share.
  • In the last 90 days, PDEX insiders reported 0 open-market purchases ($0) and 13 open-market sales ($1.4M) on Form 4, a net sale of $1.4M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2026
$77.5M
+16.5% vs prior year
Insiders · 90 days
0 buys · 13 sells
Net −$1.4M
13F holders
17 funds
$34.7M · +2 vs prior quarter
Latest 8-K
Nov 19, 2026
Item 5.07

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Jun 30, 2026

Full analysis →

Management Discussion & Analysis

  • Revenue $77.5M, up 16% YoY from $66.6M; medical device sales best performer, up $14.4M (30%) to $62.1M; repairs down 33% to $12.5M
  • Operating income $13.0M (16.8% margin) vs $10.7M (16.1% margin); net income $13.7M vs $9.0M; gross margin 31.4% vs 29.3%
  • Medical Devices segment best with $62.1M sales, +30%; Repairs worst, down $6.0M (33%) to $12.5M due to product transition
  • Operating cash flow $7.2M vs negative $1.7M; investing cash inflow $3.9M due to $11.2M proceeds from Monogram sale offset by $6.5M APM acquisition; $3.4M used in share repurchases (79,898 shares)
  • Backlog declined to $32.9M from $50.4M due to timing, orthopedic sales expected stable through 2028; FY27 repair revenue from new handpiece to begin but volumes uncertain

Risk Factors

  • Regulatory risk from U.S. Government export controls (ITAR, EAR) and government contracting post-APM acquisition in Feb 2026, with risk of penalties or contract loss
  • Geopolitical/macro risk from U.S. tariff increases starting Q1 2025 impacting costs due to complex international supply chain and raw material imports
  • Operational risk from customer concentration: top 3 customers make up 92% sales; largest customer 78%, with purchase commitments only through 2028
  • Competitive risk from larger surgical device firms and customers' internal development teams potentially eroding market share and pricing power
  • Financial risk from dependence on key personnel in product development and senior management, risking disruption if lost due to small employee base

Business Overview

  • Core business model: design, development, manufacture of autoclavable, battery-powered surgical drivers and shavers primarily for orthopedic, thoracic, and CMF markets
  • New segment introduced: precision machined parts and assemblies for aerospace and defense via acquired subsidiary Advanced Precision Machining, LLC (APM) in Feb 2026
  • Strategic shift: acquisition of APM to support increased demand from largest customer and expand machined parts business into aerospace/defense sectors
  • Employee count increased to 206 in FY 2026 from 181 in FY 2025, with employee turnover rising to 21% vs 16% prior year
  • Notable decline in backlog to $32.9 million at June 30, 2026 from $50.4 million at June 30, 2025 reflecting order variability and timing

AI summary of the PDEX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors from the June 30, 2026 Form 10-K
  • Carried-forward business risk: factors may adversely affect future financial condition and results
  • Carried-forward disclosure risk: additional uncertainties appear in financial statement notes and MD&A
  • Carried-forward completeness risk: disclosed risks may not include all future business uncertainties

Management Discussion & Analysis

  • Revenue $20.6M, up 11% YoY from $18.5M, led by medical devices at $17.4M
  • Gross margin 33% vs 29% YoY, with gross profit $6.9M vs $5.4M
  • Orthopedic sales $12.8M, up 16%; repair revenue $2.1M, down 44%
  • Cash $11.8M vs $8.2M, operating cash flow $6.5M vs $2.3M
  • Backlog $43.1M, supplier shipment delays risk handpiece deliveries; $11M revolving capacity available

AI summary of the PDEX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 19, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All seven director nominees elected, preserving the existing board’s composition
  • Director support varied: Nicholas J. Swenson received 1,811,400 votes, the lowest among nominees
Filed Nov 16, 2026Full analysis →

Item 2.03: Creation of a Direct Financial Obligation

  • UMB credit agreement amendment creates or modifies a direct financial obligation for Pro-Dex
  • Investors should review Item 1.01 for borrowing terms, collateral, covenants and maturity details

Item 1.01: Entry into a Material Definitive Agreement

  • $8.51M Term Notes C and D consolidated into amended Term Note D, eliminating Term Note C
  • Term Note D maturity extended to November 1, 2031, with fixed 6.67% interest
Filed Oct 30, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • APM secured Costa Mesa facilities through September 2030, supporting manufacturing, warehouse and office continuity
  • Existing 2,500-square-foot leases extended with base-rent increases of 4.0% to 6.6% beginning February 2027

AI summaries of PDEX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PDEX

Don't miss the next PDEX filing

  • Alerts as it files. A push when PDEX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PDEX, by share count.
  • Ask anything. An AI agent that reads every PDEX filing and answers with sources.

PDEX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Van Kirk Richard Lee JrSellSep 11, 2026$58.94
Van Kirk Richard Lee JrSellSep 11, 2026$59.62
Van Kirk Richard Lee JrSellSep 9, 2026$59.45
Van Kirk Richard Lee JrSellSep 9, 2026$62.93
Van Kirk Richard Lee JrSellSep 9, 2026$58.66
Van Kirk Richard Lee JrSellSep 9, 2026$64.70
Van Kirk Richard Lee JrSellSep 9, 2026$60.72
Van Kirk Richard Lee JrSellSep 9, 2026$59.84

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Revenue-$66.6M$77.5M
Gross Profit$14.6M$19.5M$24.3M
Operating Income-$10.7M$13.0M
Net Income-$9.0M$13.7M
Gross Margin-29.3%31.4%
Op. Margin-16.1%16.8%
Net Margin-13.5%17.6%
Balance Sheet
Total Assets$52.5M$61.2M$74.5M
Equity-$36.6M$47.6M
ROE-24.5%28.7%
Per Share
EPS-$2.67$4.12
Cash Flow
Operating CF--$1.7M$7.2M
CapEx-$1.2M$483K

Source: XBRL data in PRO DEX INC (PDEX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PDEX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PDEX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202617$34.7M
Q2 202615$25.3M
Q1 202615$24.2M
Q4 202513$19.4M
Q3 202513$18.2M
Q2 202515$22.5M
Q1 202513$16.4M
Q4 20248$12.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 109 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PDEX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 19, 2026Analysis-
8-KNov 16, 2026Analysis-
8-KOct 30, 2026Analysis-
8-KOct 29, 2026Analysis-
10-QOct 29, 2026Analysis
8-KSep 18, 2026Analysis-
4Sep 14, 2026--
4Sep 10, 2026--
4Sep 10, 2026--
10-KSep 3, 2026Analysis
8-KSep 3, 2026Analysis-
8-KAug 28, 2026Analysis-
4Jul 24, 2026--
4Jul 14, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
8-KJun 17, 2026Analysis-
10-QApr 30, 2026Analysis
8-KApr 30, 2026Analysis-
8-KMar 27, 2026--
8-KFeb 12, 2026-
8-KJan 29, 2026-
10-QJan 29, 2026Analysis
4Jan 23, 2026-

Related Health Care companies

All Health Care →

PDEX SEC filings: frequently asked questions

Are PDEX insiders buying or selling?

In the last 90 days, PRO DEX INC (PDEX) officers, directors and 10% owners reported no open-market purchases and 13 open-market sales worth $1.4 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold PDEX stock?

As of September 30, 2026, the largest PRO DEX INC (PDEX) holders among the 13F filers tracked by SignalX were BlackRock ($10.8 million), Vanguard Capital Management LLC ($5.3 million), Dimensional Fund Advisors ($4.3 million), State Street Corp ($2.7 million), D.E. Shaw & Co ($2.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PDEX's revenue in fiscal year 2026?

For the fiscal year ended June 30, 2026 (FY2026), PRO DEX INC (PDEX) reported revenue of $77.5 million (up 16.5% from FY2025) and net income of $13.7 million. Diluted EPS was $4.12. The figures come from the XBRL data in the 10-K.

What are the main risks in PDEX's latest 10-K?

In the 10-K filed September 3, 2026, PRO DEX INC (PDEX) flagged: Regulatory risk from U.S. Government export controls (ITAR, EAR) and government contracting post-APM acquisition in Feb 2026, with risk of penalties or contract loss. Geopolitical/macro risk from U.S. tariff increases starting Q1 2025 impacting costs due to complex international supply chain and raw material imports. (AI summary of the Risk Factors section.)

What did PDEX report in its latest 8-K?

PRO DEX INC (PDEX) filed an 8-K on November 19, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). All seven director nominees elected, preserving the existing board’s composition.

What are the latest PDEX SEC filings?

PRO DEX INC (PDEX) filed its latest 10-K annual report on September 3, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on September 14, 2026.

What is PDEX's SEC CIK number?

PRO DEX INC (PDEX)'s SEC Central Index Key (CIK) is 788920. EDGAR lists every PDEX filing under that number.

Ask anything about PDEX

The research agent reads PDEX's filings, financials, insider trades and 13F holders, then answers with sources.